Aigen Investment Management LP Buys 156,014 Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

Aigen Investment Management LP raised its stake in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) by 3,677.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 160,257 shares of the specialty pharmaceutical company’s stock after acquiring an additional 156,014 shares during the period. Aigen Investment Management LP owned approximately 0.17% of BioDelivery Sciences International worth $607,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BDSI. Great West Life Assurance Co. Can bought a new stake in shares of BioDelivery Sciences International in the 4th quarter worth about $36,000. C M Bidwell & Associates Ltd. bought a new stake in shares of BioDelivery Sciences International in the 4th quarter worth about $40,000. Point72 Hong Kong Ltd increased its holdings in shares of BioDelivery Sciences International by 1,133.5% in the 4th quarter. Point72 Hong Kong Ltd now owns 6,747 shares of the specialty pharmaceutical company’s stock worth $43,000 after buying an additional 6,200 shares during the last quarter. Bank of Montreal Can increased its holdings in shares of BioDelivery Sciences International by 42.4% in the 4th quarter. Bank of Montreal Can now owns 10,436 shares of the specialty pharmaceutical company’s stock worth $66,000 after buying an additional 3,108 shares during the last quarter. Finally, Trexquant Investment LP bought a new stake in shares of BioDelivery Sciences International in the 4th quarter worth about $72,000. Institutional investors own 69.14% of the company’s stock.

BDSI has been the topic of a number of research reports. Zacks Investment Research downgraded shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating and set a $4.50 target price on the stock. in a report on Tuesday, March 10th. BidaskClub upgraded shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. ValuEngine upgraded shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Tuesday, February 25th. Finally, Northland Securities initiated coverage on shares of BioDelivery Sciences International in a report on Wednesday, April 22nd. They set an “outperform” rating and a $9.00 price target on the stock. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $7.90.

Shares of NASDAQ:BDSI opened at $4.62 on Friday. The company has a market capitalization of $461.56 million, a price-to-earnings ratio of 24.32 and a beta of 0.77. BioDelivery Sciences International, Inc. has a 12 month low of $2.85 and a 12 month high of $7.21. The firm’s 50-day moving average is $4.37 and its 200 day moving average is $5.23. The company has a current ratio of 2.19, a quick ratio of 1.94 and a debt-to-equity ratio of 0.77.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.01 by $0.04. The company had revenue of $38.28 million for the quarter, compared to the consensus estimate of $33.19 million. BioDelivery Sciences International had a negative net margin of 5.01% and a positive return on equity of 23.61%. As a group, equities analysts forecast that BioDelivery Sciences International, Inc. will post 0.19 EPS for the current fiscal year.

In other BioDelivery Sciences International news, Director Mark A. Sirgo sold 100,000 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $4.58, for a total value of $458,000.00. Following the completion of the sale, the director now directly owns 1,364,595 shares of the company’s stock, valued at approximately $6,249,845.10. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Francis E. Odonnell, Jr. sold 38,750 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $3.60, for a total transaction of $139,500.00. Following the completion of the sale, the director now directly owns 611,254 shares of the company’s stock, valued at $2,200,514.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 349,249 shares of company stock valued at $1,561,729. 8.94% of the stock is owned by corporate insiders.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies.

Read More: After-Hours Trading

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.